Vanguard Global Advisers
CCCC icon

Vanguard Global Advisers’s C4 Therapeutics CCCC Stock Holding History

Vanguard Global Advisers’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Hold
33,832
– – ﹤0.01% 2593
2026
Q1 		$89K Buy
+33,832
New +$79.7K ﹤0.01% 2769

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Global Advisers's CCCC Position: Q2 2026 in Review

Vanguard Global Advisers held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 33,832 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Vanguard Global Advisers first reported a position in CCCC in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Vanguard Global Advisers held 33,832 shares of C4 Therapeutics worth $158K as of Q2 2026.
  • Vanguard Global Advisers left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2593 holding.
  • Vanguard Global Advisers first reported a position in C4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.